The American College of Rheumatology has released two new provisional definitions for rheumatoid arthritis remission that will be applied to future trials.
The American College of Rheumatology has released two new provisional definitions of rheumatoid arthritis (RA) remission, which are to be applied to future RA clinical trials.
According to research published in Arthritis & Rheumatism, a person with RA who is enrolled in a clinical trial would need to meet one of the following definitions to be considered in remission:
According to the investigators, RA disease activity is generally characterized by joint swelling and tenderness and is also reflected by increased blood levels of C-reactive protein, which is a laboratory measure of inflammation. In addition, assessments by the patient and the health professional examining the patient also reflect the extent of disease activity. These measures, among others, have been thoroughly reviewed by the investigators of this study and helped them arrive at the above provisional definitions.
The ACR and the European League Against Rheumatism, together with the Outcome Measures in Rheumatology Initiative, convened a committee to create a definition of RA remission that could be used by rheumatologists involved in clinical trials.
“There has been no widely-used definition of remission that is stringent, but achievable, and that could be applied uniformly as an outcome measure in clinical trials,” said David T. Felson, MD, one of the study investigators. “Understanding this disconnect between treatment advances and the current definition of remission—which was created in 1981 by the ACR—led our committee to focus on redefining remission so RA researchers could begin to test new definitions to see if they hold up in clinical trials."
At the beginning of its research, the committee agreed that remission had to meet a definition of little, if any, disease activity. Looking at the ACR's core set of disease activity measures in RA, each committee member was surveyed to determine what the highest cut-off point for each of these should be for a person to be considered in remission. The results of this survey led to a group of candidate definitions of remission, and each of these definitions were tested against each other and compared to the outcomes of existing RA trials.
"We identified a list of situations that might indicate someone is in remission. Then, we took each one of these candidate definitions of remission and examined how useful they would have been if used in existing RA trials," says Maarten Boers, MD, PhD, MSc, an investigator in the study. "Essentially, we wanted to know if a candidate definition of remission would have added value to, and successfully predicted a good outcome in, RA clinical trials."
The committee not only focused on whether a candidate definition of remission would offer clinical proof that joint damage had been halted, but also focused on functional outcomes of remission—namely, whether a patient could accomplish daily activities optimally.
After reviewing how each candidate definition would work in existing RA trials, and determining how a patient's assessment of overall health and pain levels would play a role in remission definitions, the committee determined that—at any point in time—an RA patient must satisfy one of the two preliminary definitions to be considered in remission.
"In a trial, one of these definitions should be chosen in advance and then if a patient in the trial meets it, he or she would be considered in remission, explained Felson." Our next steps will be to evaluate how useful and accurate these definitions are when incorporated into clinical practice."
To access the Arthritis & Rheumatism article, click here.
Source: American College of Rheumatology